Q2 2020 · —
Revenue$0.00$0.00 no prior Q2 2019 on fileno prior Q1 2020 on file
Net Income-$15.72M-$15.72M no prior Q2 2019 on fileN/M vs Q1 2020
EPS Diluted-$2.90-$2.90 no prior Q2 2019 on fileN/M vs Q1 2020
Operating Income-$15,539,000—
Operating Cash Flowderived-$12,595,000—
Free Cash Flowderived-$14,843,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q2 2019 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR